QingSong Health Corporation Announces Major Milestone: AI Evidence-Based Medical Agent “QSevidence” Officially Integrated into QSmedical Platform

Key Highlights

• Successful Integration: QingSong Health Corporation (“the Company”) has officially embedded its self-developed AI evidence-based medical agent product, QSevidence, into its proprietary QSmedical platform for medical professionals.
• Significant User Growth: As of March 31, 2026, the “QSmedical” platform, now powered by QSevidence, has reached 69,615 medical professional users, up 46.4% from 47,554 the prior year.
• Strong Penetration in Ophthalmology: The number of ophthalmology medical professional users surged to 3,672, a remarkable 171.0% year-on-year increase from 1,355.
• High Senior Physician Engagement: Of the total users, 36,678 (52.7%) are physicians at or above the level of associate chief physician, up 42.7% from 25,701 the previous year.
• Strategic AI Framework: The Company revealed a clear, progressive three-tier AI strategy based on its proprietary AIcare technology stack.

In-Depth Article for Investors

QingSong Health Corporation has made a strategic announcement that could be of significant importance to shareholders and the broader investment community. The Company’s cutting-edge AI evidence-based medical agent, QSevidence, has now been fully embedded into the Group’s QSmedical platform, which is dedicated to providing professional services to physicians and other medical professionals.

This integration is not merely technical; it represents a product-level synergy between QingSong Health’s self-developed medical AI capabilities and its proprietary physician service network. QSevidence is designed around rigorous evidence-based medical methodology, tailored for real-world clinical scenarios. Importantly, it offers physicians interpretable, verifiable, and traceable medical decision support, elevating the role of AI from simple question-answering to supporting complex, evidence-based clinical decisions.

The latest internal data as of March 31, 2026, demonstrates the platform’s surging adoption:

• Total Medical Professional Users: 69,615, up 46.4% year-on-year.
• Ophthalmology Users: 3,672, up 171.0% year-on-year.
• Senior Physicians (Associate Chief or Above): 36,678, accounting for 52.7% of all users, up 42.7% year-on-year.

This robust growth signals accelerating acceptance and reliance on digital, AI-powered decision support among frontline clinicians, especially at the senior level—a valuable user demographic for platform monetization and influence in the medical sector.

The Company’s Board highlights that the integration of QSevidence into QSmedical establishes a powerful framework, combining the Group’s advanced AI with its large-scale physician network. This synergy is expected to enable leading AI capabilities to directly support clinical decision-making and professional development for medical professionals. The favorable user structure, particularly the strong representation of senior physicians, underlines the platform’s growing professional depth and influence.

The Board believes this progress lays a solid foundation for continued expansion in evidence-based medical assistance, digital professional services, and AI-driven intelligent healthcare. The ongoing growth of the platform’s high-value user base strengthens the Company’s competitive position and could drive future revenue and market share in the rapidly evolving digital healthcare sector.

Strategic AI Roadmap

QingSong Health has outlined a three-tier progressive AI strategy based on its proprietary AIcare technology stack:

1. Infrastructure Foundation: i-DataCloud, providing AI infrastructure capabilities for all business scenarios.
2. Core Model: Dr.GPT—a vertical medical large language model supporting the intelligence of the entire healthcare services ecosystem.
3. Vertical Agent Applications: QSevidence series of evidence-based medical agent products, focusing on advanced medical scenarios for professional physicians and extending the Group’s AI capabilities into more serious medical domains.

The Group will continue to deepen its focus on medical and healthcare verticals, especially in areas such as evidence-based medicine, clinical decision-making, physician services, and public health management. The long-term vision is to build a comprehensive AI service matrix, spanning both professional and user domains, and to drive the digital and intelligent upgrade of medical and healthcare services. This ongoing innovation is expected to inject sustained momentum into QingSong Health’s long-term, high-quality development trajectory.

Implications for Shareholders and Share Price

• The integration of QSevidence with QSmedical marks a major technological and commercial milestone, potentially enhancing the Company’s value proposition and competitive edge.
• Rapid user base growth, especially among senior physicians, may signal increased platform utility and potential for future monetization.
• The three-tier AI strategy demonstrates a clear roadmap for continued innovation and market expansion in digital healthcare and AI-driven medical services.
• These developments could prove price-sensitive, as they may significantly affect the Company’s growth outlook, market positioning, and potential for long-term shareholder value creation.

Board and Leadership

The announcement was made under the authority of Ms. Yang Yin, Chairlady of the Board, Executive Director, and CEO. The Company’s leadership team consists of a balanced mix of executive, non-executive, and independent non-executive directors, ensuring strong corporate governance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to exercise caution when dealing in shares of QingSong Health Corporation and to consider their own circumstances and consult professional advisors before making any investment decisions. The Company’s Board expressly disclaims any liability for losses arising from reliance on the contents of this article.

View QINGSONG HEALTH Historical chart here